NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. was incorporated as a clinical-stage biotechnology firm without a disclosed founding year or named founders in public records. The company's wealth origin is not publicly attributed to a single family or principal, operating instead as a publicly traded entity that also engages institutional and retail investors through capital markets. The firm's strategy centers on developing therapies for neurodegenerative disorders, with a pipeline that includes primeC, a novel combination drug for ALS that completed a Phase 2b trial, and other candidates for Alzheimer's disease and Parkinson's disease. NeuroSense funds its operations through equity offerings and partnerships, with a confirmed clinical-stage approach that targets shared pathological pathways such as RNA regulation and protein aggregation (per public filings). Geographic footprint is primarily Israel-based with operations extending to the US for regulatory and clinical activities. As of mid-2025, NeuroSense had not disclosed a total deployment figure or team size. The firm maintains no publicly listed additional offices beyond its stated headquarters. Adjacent structures include publicly traded shares on Nasdaq under the ticker NRSN, which provides a capital-formation vehicle distinct from a private family office. No philanthropic foundation or operating business arm was identified in public records. A key structural differentiator is NeuroSense's hybrid model as a publicly traded biotechnology firm that retains characteristics of a development-stage company, funding clinical trials through public markets rather than private capital alone. This structure gives it a distinct regulatory posture compared to privately held biotech firms, with disclosure obligations under SEC regulations.